Antengene Corporation Limited (SEHK: 6996.HK), a China-based biopharmaceutical company, announced on Thursday that it has named Kevin Lynch MD as its new chief medical officer.

In the new role, Lynch will be responsible for the strategy, direction, and execution of the company's clinical development plans and will report directly to Dr Jay Mei, Antengene founder, chairman and CEO.

Lynch has around 30 years of experience in R&D in the pharmaceutical industry. He has served at Novartis and Celgene. He has been involved in the clinical development of multiple transformational cancer therapies, including Glivec, Tasigna, Zometa, Femara, Revlimid, Pomalyst, and Vidaza.